Abstract:
In recent years, liver cancer has grown to become one of the most challenging and
prevalent issues in the healthcare sector with millions of deaths each year. However, the
issue with the disease lies in the late diagnosis and weak prognosis of the majority of
patients. Moreover, conventional treatments are highly toxic and unaffordable for the
majority of patients. Our study investigates the anticancer efficacy of Dihydroquercetin
compound, on HepG2 cell lines of liver cancer shown promising antioxidant and anti inflammatory properties. In silico and Invitro analysis of Dihydroquercetin ligand was
performed using ADMET analysis, Pharmacophore analysis and GCMS analysis to
understand the metabolomics of Liver cancer. Our results demonstrated strong binding
affinity of DHQ with Serine/threonine-protein kinase mTOR which had a vina score of -
8.3 which showed potential for being used as a target metabolite for the drug, and
through this we can downregulate the glycolysis pathway in cancer cells. This research
will help researchers to further investigate on creating more effective and anti-cancer
drugs which will have a significant impact on survival rate.
